Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01396941 · ClinicalTrials.gov registry record · NA

Effects of Sleep Duration and Architecture on Insulin Sensitivity

A NA study of Insulin Resistance, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT01396941 is a NA study of Insulin Resistance that has completed, run by University of California, San Francisco. The registered enrollment target is 10 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01396941, a NA study of Insulin Resistance, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This pilot clinical trial will test the hypotheses that sleep restriction (for 5 nights), in comparison to "normal sleep", will: 1. Decrease peripheral insulin sensitivity and glucose tolerance, as measured by the hyperinsulinemic-euglycemic clamp and oral glucose tolerance test. 2. Decrease hepatic insulin sensitivity, as assessed by stable isotope studies of endogenous glucose production, gluconeogenesis and glycogenolysis.

Conditions Studied

Interventions

  • BEHAVIORAL Sleep restriction

Study Locations (1)

California

  • UCSF San Francisco General Hospital - San Francisco

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2011-05
Est. Completion 2014-12
Phase NA

What the Registry Record Tells You About NCT01396941

The ClinicalTrials.gov registry entry for NCT01396941 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (96% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which Sleep restriction is the first listed.

NCT01396941 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01396941 about?

NCT01396941 is a clinical study titled "Effects of Sleep Duration and Architecture on Insulin Sensitivity". This pilot clinical trial will test the hypotheses that sleep restriction (for 5 nights), in comparison to "normal sleep", will: 1. Decrease peripheral insulin sensitivity and glucose tolerance, as measured by the hyperinsulinemic-euglycemic clamp and oral glucose tolerance test. 2. Decrease hepati...

What is the current status of trial NCT01396941?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2011-05. Estimated completion is 2014-12.

What conditions does trial NCT01396941 study?

This clinical trial studies the following conditions: Insulin Resistance.

What interventions are being tested in trial NCT01396941?

The interventions under investigation include: Sleep restriction (BEHAVIORAL).

Who is sponsoring clinical trial NCT01396941?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01396941 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.